The next steps for TGR-1202 and targeting the gene c-Myc

Owen A O’Connor, MD, PhD from the Columbia University Medical Center Center for Lymphoid Malignancies, New York, NY, discusses the next steps for studying TGR-1202, which is a novel, next generation PI3K-delta inhibitor with promising activity in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). He also talks about findings concerning the targeting of oncogenes such as c-Myc in aggressive lymphomas, particularly diffuse large B-cell lymphoma (DLBCL).
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.

Share this video